Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices

General Hospital Psychiatry

Volumn 31, Issue 6, 2009, Pages 531-537

  Weiss, Jeffrey J ^a   Morgello, Susan ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; HIV HCV coinfection; Interferon; Ribavirin

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; PEGINTERFERON; RIBAVIRIN;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DRUG WITHDRAWAL; E-MAIL; EVIDENCE BASED MEDICINE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; MALE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL RESEARCH; MENTAL HEALTH CARE; MENTAL INSTABILITY; NORMAL HUMAN; ONLINE SYSTEM; PRESCRIPTION; PSYCHIATRIST; SIDE EFFECT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; COMORBIDITY; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH SERVICES RESEARCH; HEALTH SURVEYS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYETHYLENE GLYCOLS; RIBAVIRIN; UNITED STATES;

EID: 70350507294     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2009.05.006     Document Type: Article

References (37)

1. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
2. Rosenthal E., Pialoux G., Bernard N., et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14 (2007) 183-188
3. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 (2006) 1632-1641
4. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
5. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
6. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
7. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
8. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
9. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
10. Shire N.J., Welge J.A., and Sherman K.E. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 14 (2007) 239-248
11. Goulet J.L., Fultz S.L., McGinnis K.A., et al. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 19 Suppl 3 (2005) S99-S105
12. Raison C.L., Broadwell S.D., Borisov A.S., et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19 (2005) 23-27
13. Reichenberg A., Gorman J.M., and Dieterich D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 19 Suppl 3 (2005) S174-S178
14. Hoffman R.G., Cohen M.A., Alfonso C.A., et al. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 44 (2003) 417-420
15. Dieperink E., Ho S.B., Tetrick L., et al. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 26 (2004) 237-240
16. Sola R., Galeras J.A., Montoliu S., et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 22 (2006) 393-400
17. Malek-Ahmadi P., and Hilsabeck R.C. Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry 19 (2007) 113-123
18. Musselman D.L., Lawson D.H., Gumnick J.F., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 (2001) 961-966
19. Morasco B.J., Rifai M.A., Loftis J.M., et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 103 (2007) 83-90
20. Raison C.L., Woolwine B.J., Demetrashvili M.F., et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 25 (2007) 1163-1174
21. Kraus M.R., Schafer A., Schottker K., et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57 (2008) 531-536
22. Loftis J.M., Matthews A.M., and Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 66 (2006) 155-174
23. Weiss J.J., and Gorman J.M. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep 3 (2006) 176-181
24. Ho S.B., Groessl E., Dollarhide A., et al. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol 103 (2008) 1810-1823
25. Sylvestre D.L., Loftis J.M., Hauser P., et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81 (2004) 719-734
26. Schaefer M., Hinzpeter A., Mohmand A., et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46 (2007) 991-998
27. Rifai M.A. Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry 8 (2006) 361-366
28. Huckans M., Mitchell A., Ruimy S., et al. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull (2008) [Electronic publication Jun 17]
29. Bruggmann P., Falcato L., Dober S., et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 15 (2008) 747-752
30. Taylor L.E. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 40 Suppl 5 (2005) S355-S361
31. Klein M.B., Cooper C., Brouillette M.J., et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials 29 (2008) 617-630
32. Cozza K.L.W.S., and Wynn G.H. Psychopharmacologic treatment issues in AIDS psychiatry. In: Cohen M.A., and Gorman J.M. (Eds). Comprehensive textbook of AIDS psychiatry (2008), Oxford University Press, New York 455-485
33. Douaihy A., Hilsabeck R.C., Azzam P., et al. Neuropsychiatric aspects of coinfection with HIV and hepatitis C virus. AIDS Read 18 (2008) 425-32, 438-9
34. Letendre S., Paulino A.D., Rockenstein E., et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 196 (2007) 361-370
35. Morgello S., Estanislao L., Ryan E., et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 19 Suppl 3 (2005) S116-S122
36. Ryan E.L., Morgello S., Isaacs K., et al. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62 (2004) 957-962
37. Raison C.L., Demetrashvili M., Capuron L., et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005) 105-123